6 research outputs found
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
BACKGROUND. Patients with acute myocardial infarction who were treated with accelerated tissue plasminogen activator (t-PA) (given over a period of 1 1/2 hours rather than the conventional 3 hours, and with two thirds of the dose given in the first 30 minutes) had a 30-day mortality that was 15 percent lower than that of pati
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study
BACKGROUND: Stroke occurs concurrently with myocardial infarction (MI) in
approximately 30 000 US patients each year. This number is expected to
rise with the increasing use of thrombolytic therapy for MI. However, no
data exist for the economic effect of stroke in the setting of acute MI
(AMI). The purpose of this prospective study was to assess the effect of
stroke on medical resource use and costs in AMI patients in the United
States. METHODS AND RESULTS: Medical resource use and cost data were
prospectively collected for 2566 randomly selected US GUSTO I patients
(from 23 105 patients) and for the 321 US GUSTO I patients who developed
non-bypass surgery-related stroke during the baseline hospitalization.
Follow-up was for 1 year. All costs are expressed in 1993 US dollars.
During the baseline hospitalization, stroke was associated with a
reduction in cardiac procedure rates and an increase in length of stay,
despite a hospital mortality rate of 37%. Together with stroke-related
procedural costs of 29 242 versus 22 400 versus
15 092 higher
than for no-stroke patients. Hemorrhagic stroke patients had a much higher
hospital mortality rate than non-hemorrhagic stroke patients (53% versus
15%, P<0.001), which was associated with approximately $7200 lower mean
baseline hospitali